Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

CraniumCap Dec. 27 at 5:05 AM

$CAPR Risk tolerance remains selective and tied closely to execution credibility. Competitive advantages must begin to appear in core metrics. Credible progress tends to compress risk premiums. Ultimately, disciplined delivery will shape the outcome.

0 · Reply

viber7 Dec. 27 at 2:13 AM

$CAPR It's interesting that no company has a good, direct method of treating DMD. SRPT gene therapy strives to correct the gene defect, but it is unsafe. CAPR corrects the damage of dystrophin malfunction. MSCLF's protein strives to restore the signal of absent dystrophin, but it is indirect like Dera. MSCLF is much more speculative than CAPR, and it is priced accordingly. It is for PUL only. One day it may go for cardio. Meanwhile, CAPR has 5-10 years before it has competition for cardio. I can imagine in 10+ years, MSCLF and CAPR will be used together for even better cardio effects. Maybe DMD patients will have full life expectancy.

1 · Reply

Gatorgunk Dec. 26 at 10:18 PM

$CAPR the legend elijah stacy and 153 of the community wrote a letter to the fda asking for AA. Sorry if this was already posted here https://www.linkedin.com/posts/elijah-stacy-208008155_153-in-the-dmd-community-have-signed-on-to-activity-7407872251989172224-h73I

2 · Reply

Bentradez Dec. 26 at 9:57 PM

$CAPR this period may look short but it stayed flat from July 23- Aug 20th before moving up again. It went on to double in the next few months. For us we are about 23 days after our initial data

0 · Reply

Cote0924 Dec. 26 at 8:56 PM

$CAPR MM must be bored buying back and forth today.

2 · Reply

wkee Dec. 26 at 8:54 PM

$CAPR

0 · Reply

FindingFacts Dec. 26 at 7:45 PM

$CAPR Parent Project Muscular Dystrophy has a proven history of working with the FDA, as it got $SRPT's drug approval. This parent project group gets congressmen's support for a quick approval of a drug to treat DMD. Be patient to get the $50 price level.

1 · Reply

SmartOptionsAlert Dec. 26 at 6:54 PM

🔎 $CAPR Options Scan Update (12:54 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

Stanleydavidson Dec. 26 at 6:43 PM

$VNDA is the next $CAPR or $OMER

0 · Reply

IEatBearsForBreakfast Dec. 26 at 5:45 PM

$CAPR waiting for that bomb to drop next week.

0 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 19 days ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 21 days ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 22 days ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 23 days ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 23 days ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 23 days ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 4 weeks ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 6 weeks ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 7 weeks ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 2 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 3 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 3 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 3 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 3 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 3 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 3 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 4 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 5 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 5 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 5 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 5 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 5 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 5 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 5 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

CraniumCap Dec. 27 at 5:05 AM

0 · Reply

viber7 Dec. 27 at 2:13 AM

1 · Reply

Gatorgunk Dec. 26 at 10:18 PM

2 · Reply

Bentradez Dec. 26 at 9:57 PM

$CAPR this period may look short but it stayed flat from July 23- Aug 20th before moving up again. It went on to double in the next few months. For us we are about 23 days after our initial data

0 · Reply

Cote0924 Dec. 26 at 8:56 PM

$CAPR MM must be bored buying back and forth today.

2 · Reply

wkee Dec. 26 at 8:54 PM

$CAPR

0 · Reply

FindingFacts Dec. 26 at 7:45 PM

1 · Reply

SmartOptionsAlert Dec. 26 at 6:54 PM

🔎 $CAPR Options Scan Update (12:54 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

Stanleydavidson Dec. 26 at 6:43 PM

$VNDA is the next $CAPR or $OMER

0 · Reply

IEatBearsForBreakfast Dec. 26 at 5:45 PM

$CAPR waiting for that bomb to drop next week.

0 · Reply

FindingFacts Dec. 26 at 5:23 PM

$CAPR is ready to take off after maximizing its offering.

1 · Reply

Beat_market_loser Dec. 26 at 5:09 PM

$CAPR where are we landed on the last day of 2025?

0 · Reply

razorsedge4343 Dec. 26 at 5:01 PM

$OMER $CAPR Jack nailed it. @jacksparo Hope you're still holding your $OMER !?

1 · Reply

zoneclassman1 Dec. 26 at 5:00 PM

$OMER $CAPR I made significant profits in those two. Thanks to the one who called them both this year, @jacksparo, one of the best!

0 · Reply

AlexNvc_22 Dec. 26 at 4:33 PM

$CAPR biotech microcap quiet accumulation needs volume

0 · Reply

dnfrs Dec. 26 at 4:03 PM

$CAPR Good questions about how Deramiocel will be priced in the US. Rare diseases frequently have expensive treatments. America has a wealthcare system...not a healthcare system. There is great healthcare for the wealthy and a poor healthcare system for the poor. Cut backs in health care funding will affect the poor. Wealthy folks(like many of us Capricor investors!) will be just fine. But viber7 raises some important points. As far as MSCLF goes it is early days. And they do not appear to be measuring cardiac function as far as I can see. Hope it works... alongside Deramiocel!

1 · Reply

viber7 Dec. 26 at 3:50 PM

$CAPR The main risk of CAPR is whether Dera will get $1 million annually per patient, $350-400 million to CAPR. SRPT got $3.2 million as one-time treatment. If Dera is used for 20-30 years, that's $20-30 million per patient, much more expensive. If most of the 15-20,000 DMD US patients are treated at $1 million each, sure the PPS could be $500+. Will MSCLF work and take over the market at much cheaper prices? Please, let's discuss. Don't waste board space with trivialities like technical trading, shorts BS, etc.

2 · Reply

pkivory1 Dec. 26 at 3:47 PM

$CAPR People keep asking when will the BLA submission be PR'ed? My guess would be January 5 or 6 after options are granted on Jan.2. Until then I wouldn't expect this to stay above 30. I would be happy to be wrong but in the end it doesn't matter. It was a job well done and Linda and co. have earned an extra taste.

3 · Reply

haha1978 Dec. 26 at 3:41 PM

$CAPR The government will cave in. They always do when its tough. Bail out every one GM, banks, politicians, and DMD patients. The government is weak and can be pushed.

0 · Reply

MoneyGroupLLC Dec. 26 at 3:36 PM

Enter: $CAPR Calls Strike Price: $30 Expiry Date: JAN 16 2026 Buy in Price: $2.60 - $2.73 Sell Price: $5.49 Profit : +111% (Turn every $1 into $2.11) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Pennyforyourbuck Dec. 26 at 3:34 PM

$CAPR when resubmission? Today or next week?

1 · Reply

1K21Mil Dec. 26 at 3:31 PM

$CAPR Happy Friday! If own shares, keep the smile and enjoy your time with family and friends. March towards $40 would begin next week.

0 · Reply

Market Cap	1.36B
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	910,100
Avg Vol	3,176,252
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	90%
Beta	0.61
Analysts	Strong Sell
Price Target	$50.80